Dane Aniek, van Leeuwen Roelof, Hoedemakers Maaike, van der Kuy Hugo, Sleijfer Stefan
Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands.
Department of Market Strategy and Healthcare Financing, Erasmus MC, Rotterdam, Netherlands.
Front Pharmacol. 2023 Aug 28;14:1264951. doi: 10.3389/fphar.2023.1264951. eCollection 2023.
Rapid increase in cost continues to have negative impact on patients' accessibility to life-changing anticancer medications. Moreover, the rising cost does not equate to similar increase in medication effectiveness. We recognise our responsibility as a university hospital to tackle this imbalance and strive to provide high quality, sustainable, affordable and accessible care. An active approach in cost containment of expensive and innovative cancer drugs was adopted in our organisation to safeguard accessibility and improve quality of life for patients. In this article, we described four inverventions: 1) identify right patient and minimise overtreatment, 2) in-house medicine production for selected indications, 3) minimise medicine spillages and 4) effective procurement strategies. We call on other hospitals to take action and, favourably, to collaborate on a European level. Together, we will safeguard the current and future care of our patients.
成本的快速增长持续对患者获取改变生命的抗癌药物产生负面影响。此外，成本的上升并不等同于药物疗效的类似提高。我们认识到作为一家大学医院，我们有责任解决这种不平衡问题，并努力提供高质量、可持续、可负担且可及的医疗服务。我们的机构采取了积极措施来控制昂贵且创新的癌症药物成本，以保障患者的可及性并改善其生活质量。在本文中，我们描述了四种干预措施：1）识别合适的患者并尽量减少过度治疗；2）针对特定适应症进行院内药品生产；3）尽量减少药品浪费；4）有效的采购策略。我们呼吁其他医院采取行动，并希望在欧洲层面进行合作。我们将共同保障我们患者当前和未来的医疗服务。
